The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...

Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...